Pulmonary conditions in athletes

1. High-Yield Summary

Pulmonary and upper airway conditions in competitive athletes represent a diverse spectrum of physiological challenges and pathological disorders that impair gas exchange, ventilatory mechanics, and athletic performance. Core clinical benchmarks and management principles include:

• The Diagnostic Discordance Trap: Self-reported respiratory symptoms (dyspnea, cough, wheeze, chest tightness) correlate poorly with objective airway pathophysiology, demonstrating diagnostic sensitivities as low as 36% to 65%. Empirical prescription of inhaled beta-2 agonists without objective bronchoprovocation testing leads to both substantial overdiagnosis and underdiagnosis in athletic cohorts.
• EIB versus EILO Differentiation: The critical clinical distinction rests on timing and respiratory phase. Exercise-Induced Bronchoconstriction (EIB) typically manifests 5 to 15 minutes post-exercise with expiratory wheezing and cough, whereas Exercise-Induced Laryngeal Obstruction (EILO) peaks at maximal exertion with inspiratory stridor and resolves within 2 to 5 minutes of workload cessation.
• Gold-Standard Objective Challenges: Eucapnic Voluntary Hyperpnea (EVH) serves as the gold-standard indirect bronchial provocation test endorsed by the International Olympic Committee (IOC) for diagnosing EIB. Continuous Laryngoscopy during Exercise (CLE) is the mandatory gold-standard modality to visualize paradoxical vocal cord adduction or supraglottic collapse in EILO.
• Strict Anti-Doping Governance: Prescription of inhaled beta-2 agonists must strictly comply with World Anti-Doping Agency (WADA) permitted dosing limits (salbutamol maximum 1,600 mcg per 24 hours, not to exceed 600 mcg in any 8-hour window; formoterol maximum 54 mcg per 24 hours; salmeterol maximum 200 mcg per 24 hours). Exceeding these thresholds constitutes an adverse analytical finding unless an approved Therapeutic Use Exemption (TUE) is documented.
• Life-Threatening Thoracic Emergencies: Clinicians must maintain heightened vigilance for Swimming-Induced Pulmonary Edema (SIPE) in open-water endurance athletes, effort thrombosis of the axillary-subclavian vein (Paget-Schroetter syndrome) in overhead throwing athletes, and primary spontaneous tension pneumothorax in tall, asthenic contact sport participants.

2. Pertinent Functional Anatomy & Thoracic Biomechanics

The human respiratory system sustains minute ventilations exceeding 150 to 200 L/min during peak endurance performance, placing extraordinary mechanical and thermodynamic stress across five discrete anatomic zones.

Tracheobronchial Tree & Airway Mucosal Barrier

The conducting airways bifurcate through 23 branching generations from the trachea down to the terminal bronchioles. Generations 0 through 16 compose the anatomic dead space, lined by pseudostratified ciliated columnar epithelium, goblet cells, and submucosal glands overlying smooth muscle bundles. A dense subepithelial microvascular plexus supplied by bronchial arteries functions as a local heat- and moisture-exchange apparatus. Under resting conditions, nasal breathing conditions inspired air to 37°C and 100% relative humidity before it passes the carina. When minute ventilation exceeds 35 to 40 L/min, the nasal threshold is surpassed, compelling an obligatory switch to oronasal breathing that delivers unconditioned, dry, cold air directly onto lower tracheobronchial surfaces.

Laryngeal Functional Anatomy & Vocal Fold Dynamics

The larynx serves as an adjustable aerodynamic valve governed by the cricoid, thyroid, and paired arytenoid cartilages. Glottic aperture is regulated by intrinsic laryngeal musculature innervated by the recurrent laryngeal nerve (branch of cranial nerve X), except the cricothyroid muscle which receives motor innervation from the external branch of the superior laryngeal nerve. The posterior cricoarytenoid (PCA) muscle is the sole abductor of the true vocal folds, contracting vigorously during inspiration to maximize glottic area. The lateral cricoarytenoid, transverse arytenoid, and oblique arytenoid muscles adduct the vocal folds. Supraglottic structures include the epiglottis, paired aryepiglottic folds, and cuneiform and corniculate tubercles. High inspiratory airflow velocities generate negative transmural intraluminal pressure gradients (Bernoulli principle) that tend to pull compliant supraglottic tissues medially into the laryngeal inlet during intense hyperpnea.

Thoracic Cage, Diaphragm & Intercostal Neurovascular Bundle

The thoracic cage consists of 12 thoracic vertebrae, 12 paired ribs, costal cartilages, and the sternum. Normal inspiration is driven by diaphragmatic contraction (phrenic nerve, C3-C5) and external intercostal muscles. During maximal athletic exertion, accessory inspiratory muscles—scalene group (anterior, medius, posterior), sternocleidomastoid, pectoralis minor, and serratus anterior—are recruited to elevate the superior ribs and clavicle. Active expiration is driven by internal intercostals and abdominal wall musculature (rectus abdominis, external and internal obliques, transversus abdominis). Along the inferior margin of each rib lies the subcostal groove housing the intercostal neurovascular bundle arranged superior-to-inferior as Vein, Artery, Nerve (VAN). Surgical tube thoracostomy and needle decompression must strictly traverse immediately superior to the lower rib margin to avoid lacerating these vessels.

Pleural Space & Pulmonary Microvasculature

The pleural space is a potential cavity bounded by the parietal pleura lining the internal thoracic wall and the visceral pleura reflecting over the lung parenchyma. Normal pleural fluid volume is approximately 0.1 to 0.2 mL/kg, maintaining sliding lubrication and coupling chest wall expansion to lung inflation via subatmospheric intrapleural pressure (-3 to -5 cm H2O at rest, dropping to -30 to -40 cm H2O during strenuous inspiration). The pulmonary circulation is a high-flow, low-resistance system accepting the entire cardiac output. Pulmonary capillary hydrostatic pressure averages 8 to 10 mmHg at rest. At peak cardiac outputs approaching 35 to 40 L/min, mean pulmonary arterial and capillary pressures rise dramatically, testing the structural limits of the thin alveolar-capillary barrier (0.2 to 0.5 micrometers).

Costoclavicular Space & Thoracic Outlet Corridor

The thoracic outlet comprises three sequential anatomical compartments: the interscalene triangle, the costoclavicular space, and the subpectoral (retropectoralis minor) space. The costoclavicular space is bounded anteriorly by the clavicle, subclavius muscle, and costoclavicular ligament; posteriorly and inferiorly by the first rib and the insertion of the anterior scalene muscle; and posterolaterally by the superior border of the scapula. The subclavian vein traverses this confined space anterior to the anterior scalene muscle, resting directly over the flat superior surface of the first rib. Repetitive hyperabduction, external rotation, and heavy shoulder girdle traction compress the vein against the rigid first rib and clavicle, predisposing to mechanical intimal injury.

3. Pathogenesis & Disease Mechanisms

The etiology of athletic pulmonary dysfunction involves distinct biomechanical, thermodynamic, and microvascular mechanisms depending on the specific anatomic structure involved.

Exercise-Induced Bronchoconstriction (EIB): Osmolar & Thermal Hypotheses

During strenuous exercise, minute ventilation increases up to twenty-fold, overwhelming the conditioning capacity of the upper airway. Two complementary models explain the resulting bronchial spasm:

• The Osmolar Hypothesis: Rapid, sustained evaporation of water from the airway surface liquid (ASL) lining bronchial epithelial cells produces local hyperosmolarity. This hyperosmolar shock draws water out of epithelial cells, causing intracellular shrinkage, calcium influx, and activation of intracellular phospholipase A2. This cascade triggers immediate degranulation of airway mast cells, eosinophils, and basophils, releasing potent bronchoconstrictor mediators including cysteinyl leukotrienes (LTC4, LTD4, LTE4), histamine, and prostaglandin D2 (PGD2). These mediators bind directly to smooth muscle receptors in the tracheobronchial tree, inducing sustained smooth muscle contraction, mucosal edema, and microvascular engorgement.
• The Thermal Hypothesis: High ventilatory volumes cool the bronchial mucosa. Following cessation of exercise, rapid passive rewarming of the bronchial walls occurs. This thermal shift produces sudden reactive hyperperfusion and engorgement of the peribronchial capillary network, causing vascular congestion, mucosal thickening, and mechanical luminal narrowing independent of smooth muscle contraction.
• Hyperpnea-Induced Epithelial Damage: Repetitive desiccation stress, high aerodynamic shear forces, and inhaled airborne pollutants (ozone, nitrogen oxides, fine particulate matter, chloramines in pools) disrupt tight junctions between ciliated epithelial cells. Epithelial shedding exposes sensory nerve terminals, amplifies cholinergic bronchoconstrictor reflexes, and induces long-term tissue remodeling.

Exercise-Induced Laryngeal Obstruction (EILO)

Unlike EIB, which affects the intrathoracic airways, EILO represents an acute, reversible narrowing of the extrathoracic airway at the laryngeal level during high-intensity exercise:

• Glottic EILO: Characterized by paradoxical, involuntary adduction of the true vocal folds during the inspiratory phase of respiration. The pathophysiology involves hyperresponsiveness of intrinsic laryngeal adductor reflexes mediated by the superior and recurrent laryngeal nerves in response to cold, dry air, turbulent flow, or mucosal irritation.
• Supraglottic EILO: Involves dynamic inward collapse of compliant supraglottic structures, including the cuneiform tubercles, aryepiglottic folds, and retroflexion of the epiglottis. When inspiratory airflow accelerates through the glottic aperture, the Bernoulli effect generates extreme negative transmural pressures that pull lax supraglottic mucosa into the airway lumen. Supraglottic collapse accounts for more than 60% of all EILO presentations in competitive athletes.

Swimming-Induced Pulmonary Edema (SIPE)

SIPE is an acute, non-cardiogenic alveolar inundation occurring in healthy athletes participating in strenuous swimming or SCUBA diving, predominantly in cold open water. The mechanism is governed by capillary stress failure:

• Hydrostatic Central Pooling: Immersion in water eliminates the hydrostatic gradient of gravity, while ambient hydrostatic pressure and cold-induced peripheral vasoconstriction compress capacitance veins in the lower extremities and splanchnic circulation. This shifts up to 500 to 800 mL of blood centrally into the thoracic cardiopulmonary reservoir, markedly increasing central venous pressure, right ventricular preload, and pulmonary arterial blood volume.
• Exertional Capillary Stress Failure: Sustained maximal swim effort elevates cardiac output, further driving mean pulmonary capillary pressures past 25 to 30 mmHg. Concurrently, breathing against negative hydrostatic pressure (especially with tight neoprene wetsuits or snorkels) generates exaggerated negative alveolar pressures during inspiration. When the transmural capillary pressure exceeds the tensile strength of the alveolar-capillary membrane, mechanical disruption (“stress failure”) of capillary endothelial cells and type I alveolar pneumocytes ensues. This causes high-permeability extravasation of proteinaceous fluid and red blood cells directly into alveolar gas spaces, manifesting as acute cough, dyspnea, and hemoptysis.

Effort Thrombosis (Paget-Schroetter Syndrome)

Paget-Schroetter syndrome represents primary deep vein thrombosis of the axillary and subclavian veins triggered by vigorous, repetitive upper extremity motion in overhead athletes (baseball pitchers, swimmers, rowers, weightlifters, volleyball players). Repetitive abduction, external rotation, and shoulder retroversion compress the subclavian vein between the clavicle, subclavius muscle, costoclavicular ligament, and the rigid first rib. This persistent scissor-like mechanical pinching causes repetitive intimal contusion, endothelial denudation, perivenous fibrosis, and local stasis (Virchow triad). Platelet aggregation culminates in acute occlusive thrombosis that threatens to propagate into the superior vena cava or embolize into the pulmonary arterial circulation.

4. Natural History, Epidemiology & Chronic Airway Remodeling

The prevalence of athletic pulmonary disorders is strongly dictated by environmental exposures, training volumes, and sports-specific ventilation dynamics.

Epidemiology Across Sporting Disciplines

While the prevalence of asthma and airway hyperresponsiveness in the general sedentary population ranges between 5% and 8%, elite endurance athletes demonstrate markedly elevated rates:

• Winter Endurance Sports (Cross-Country Skiing, Biathlon, Speed Skating): Prevalence of EIB ranges from 30% to 70%. Inhaling unconditioned air at temperatures below -15°C causes profound mucosal desiccation, freezing injury to epithelial cells, and persistent inflammatory cascades.
• Aquatic Sports (Swimmers, Water Polo): Prevalence of EIB ranges from 25% to 50%. Chronic inhalation of volatile disinfection byproducts—principally trichloramines (nitrogen trichloride) accumulating at the water-air interface—causes direct chemical cytotoxicity and increases epithelial permeability.
• Endurance Running & Cycling: EIB prevalence ranges from 15% to 25%, driven by sustained high-volume hyperpnea and ambient aerobiology (fine particulate matter PM2.5, ozone, seasonal aeroallergens).
• Exercise-Induced Laryngeal Obstruction (EILO): Affects approximately 5% to 7% of adolescent and young adult athletes, with a pronounced female-to-male predilection (2:1 to 3:1). Peak incidence occurs between ages 14 and 22, frequently coinciding with competitive athletic specialization.

Chronic Airway Remodeling & Long-Term Prognosis

Left unmanaged, repetitive epithelial shearing and chronic neurogenic and mediator-driven inflammation culminate in structural airway remodeling. Histopathological analyses of bronchial biopsies from elite cross-country skiers reveal marked thickening of the subepithelial reticular basement membrane, goblet cell metaplasia, tenascin and fibronectin deposition, and hypertrophy of airway smooth muscle bundles. Unlike classic childhood atopic asthma, athletic “ski asthma” is frequently non-atopic and characterized by mixed neutrophilic and eosinophilic inflammation. Follow-up investigations in retired endurance athletes demonstrate that while bronchial hyperresponsiveness and mucosal inflammation attenuate significantly within 2 to 5 years after cessation of elite training, fixed structural changes and persistent subepithelial fibrosis can remain permanent in a subset of athletes.

5. Clinical Presentation & Diagnostic Maneuvers

Accurate clinical diagnosis requires systematic history taking focused on symptom chronometry, complemented by targeted provocative physical examination maneuvers.

History & Symptom Stratification

Clinicians must delineate the precise temporal and mechanical features of respiratory distress:

• Onset & Peak of Symptoms: Symptoms developing during low-intensity warmup or within the first 2 minutes of exertion suggest poor aerobic conditioning or vocal cord dysfunction. Symptoms peaking at maximal exertional intensity point toward EILO. Symptoms developing or worsening 5 to 15 minutes after stopping exercise are hallmark features of EIB.
• Respiratory Phase & Acoustic Signature: Expiratory wheeze, persistent hacking cough, chest tightness, and excess sputum production indicate lower airway constriction (EIB). High-pitched inspiratory stridor, throat tightness, localized tracheal choking sensation, and inability to pull air inward point toward upper airway obstruction (EILO).
• Environmental Context: Symptoms exacerbated exclusively by sub-zero temperatures, chloramine odor in indoor pools, or specific outdoor training courses help isolate external triggers.
• Red Flag Symptoms: Pink frothy sputum, hemoptysis, and profound hypoxemia during open-water swimming indicate acute SIPE. Acute unilateral upper extremity swelling, cyanosis, and deep axillary pain following overhead throwing or rowing indicate acute subclavian vein effort thrombosis. Sudden pleuritic chest pain and unilateral dyspnea during play indicate pneumothorax.

Physical Examination & Provocative Maneuvers

At rest, physical examination of the pulmonary system and chest wall in high-performance athletes is almost invariably normal. Diagnostic yield relies entirely on structured provocation:

• Eucapnic Voluntary Hyperpnea (EVH) Provocation: Target ventilation at 85% of Maximum Voluntary Ventilation (MVV) for 6 minutes inhaling dry gas with 5% CO2 -> Sustained post-challenge FEV1 reduction of >= 10% [Sensitivity 90-95%, Specificity 88-92%].
• Continuous Laryngoscopy during Exercise (CLE): Transnasal fiberoptic video laryngoscopy secured during incremental treadmill or cycle ergometer exercise to volitional exhaustion -> Direct visualization of paradoxical vocal fold adduction or supraglottic collapse at peak exercise [Sensitivity 92-95%, Specificity 94-98%].
• Immediate Post-Exertion Serial Auscultation: Auscultation of lung fields at 3, 5, 10, and 15 minutes post-maximal exercise -> Detection of polyphonic end-expiratory wheezing or basilar crackles (SIPE) [Sensitivity 45-55%, Specificity 85-90%].
• Costoclavicular Compression Test (Military Brace Maneuver): Patient retracts and depresses shoulders while thrusting chest forward with neck hyperextended -> Obliteration of radial pulse and replication of upper extremity paresthesia or venous engorgement [Sensitivity 60-70%, Specificity 65-75%].
• Wright’s Hyperabduction Test: Passive hyperabduction and external rotation of the arm past 90 degrees with head rotated contralaterally -> Radial pulse dampening or reproduction of ischemic/venous arm symptoms [Sensitivity 55-65%, Specificity 70-80%].

6. Imaging and Diagnostic Studies

The diagnostic pathway progresses from non-invasive laboratory provocation to dynamic endoscopic visualization and specialty cross-sectional vascular imaging.

Eucapnic Voluntary Hyperpnea (EVH) Testing

EVH is the definitive gold-standard challenge test endorsed by the IOC Medical Commission and the American Thoracic Society (ATS) for confirming EIB in athletes. The athlete breathes a dry compressed gas mixture (21% O2, 5% CO2, balance N2) at a target ventilation rate equal to 85% of Maximum Voluntary Ventilation (calculated as baseline FEV1 multiplied by 30 or 35) for 6 consecutive minutes. The 5% CO2 prevents hypocapnia and respiratory alkalosis. Spirometry is performed at baseline and at 3, 5, 10, 15, and 20 minutes post-challenge. A reduction in FEV1 of >= 10% from baseline at two consecutive time points constitutes an objective positive test. A fall of 10% to 24.9% indicates mild EIB; 25% to 49.9% indicates moderate EIB; and >= 50% indicates severe EIB.

Continuous Laryngoscopy During Exercise (CLE)

CLE provides definitive real-time video evaluation of upper airway collapse during active exertion. A flexible fiberoptic nasendoscope is passed through the nasal cavity into the hypopharynx and secured to a customized headgear apparatus. The athlete performs incremental ramp exercise on a treadmill or cycle ergometer until maximal exertion is reached. CLE captures dynamic laryngeal movement throughout the entire exercise cycle, allowing quantitative grading of glottic and supraglottic collapse according to validated classification criteria.

Resting Spirometry & Bronchodilator Reversibility

Standard resting spirometry evaluates baseline FEV1, forced vital capacity (FVC), and the FEV1/FVC ratio. While an FEV1/FVC ratio below the lower limit of normal (LLN) or below 0.70 confirms airflow limitation, the vast majority of athletes with EIB have supranormal baseline resting lung function (FEV1 often 110% to 130% of predicted). A positive bronchodilator reversibility test (>= 12% and >= 200 mL increase in FEV1 15 minutes after 400 mcg of inhaled salbutamol) confirms underlying asthma but lacks sensitivity for isolated EIB.

Chest Radiography & Computed Tomography (CT)

Standard posteroanterior (PA) and lateral chest radiographs are indicated when acute pathology is suspected:

• Pneumothorax: Erect expiratory PA radiograph demonstrates displacement of the visceral pleural white line away from the chest wall, absent peripheral vascular markings, and deep sulcus sign. In tension pneumothorax, ipsilateral diaphragmatic flattening and contralateral mediastinal deviation are emergency findings.
• Swimming-Induced Pulmonary Edema (SIPE): Chest radiography demonstrates bilateral perihilar ground-glass opacities, alveolar infiltrates, and interstitial Kerley B lines with a normal cardiothoracic ratio, typically resolving completely within 24 to 48 hours.
• Computed Tomography: High-resolution CT (HRCT) of the chest evaluates apical subpleural blebs and bullae in athletes with primary spontaneous pneumothorax. Contrast-enhanced CT pulmonary angiography (CTPA) is the primary modality when pulmonary embolism secondary to upper extremity deep vein thrombosis is suspected.

Upper Extremity Duplex Ultrasound & Digital Subtraction Venography

In athletes presenting with suspected effort thrombosis (Paget-Schroetter syndrome), color duplex ultrasonography with dynamic postural maneuvers (neutral, 90-degree abduction, and full hyperabduction) is the primary first-line test. Positive findings include intraluminal echogenic thrombus, non-compressibility of the axillary vein, and absence of respiratory flow phasicity. Digital subtraction venography performed via transbrachial or antecubital access remains the definitive imaging gold standard, identifying the precise point of costoclavicular venous compression, extent of thrombus, and extensive web-like collateral drainage corridors.

7. Classification Systems

Athletic pulmonary and thoracic vascular disorders are categorized based on anatomical location, physiological mechanism, diagnostic gold standard, and primary clinical management.

For EILO, the validated continuous laryngoscopy exercise (CLE) scoring system grades laryngeal narrowing at peak exercise separately for the glottic and supraglottic levels:

8. Treatment & Management Algorithms

Management of pulmonary disorders in athletes demands a structured balance between clinical efficacy, non-pharmacologic optimization, and strict adherence to international anti-doping regulations.

Medical & Nonoperative Therapy

Pharmacotherapy for EIB follows a stepwise escalation protocol coupled with anti-doping compliance:

• Step 1 (Mild / Intermittent EIB): Inhaled Short-Acting Beta-2 Agonist (SABA, e.g., salbutamol 200 to 400 mcg) administered 15 to 20 minutes prior to exercise. SABA provides rapid bronchodilation and prevents mediator release for 2 to 4 hours. Daily monotherapy with SABA is strictly avoided, as frequent administration down-regulates beta-2 adrenergic receptors, induces tolerance (tachyphylaxis), and exacerbates rebound bronchoconstriction.
• Step 2 (Persistent EIB / Incomplete SABA Response): Initiate regular daily anti-inflammatory maintenance therapy with low-to-medium dose Inhaled Corticosteroids (ICS, e.g., budesonide 200 to 400 mcg twice daily or fluticasone propionate 100 to 250 mcg twice daily). Regular ICS therapy suppresses airway mucosal inflammation, reduces baseline hyperresponsiveness, and restores beta-2 receptor sensitivity over a 2- to 4-week window.
• Step 3 (Moderate-to-Severe Refractory EIB): Combine daily ICS with a Long-Acting Beta-2 Agonist (LABA, e.g., formoterol or salmeterol) in a fixed-dose single inhaler. In accordance with Global Initiative for Asthma (GINA) and ATS guidelines, LABA monotherapy is absolutely contraindicated due to increased risk of severe asthma exacerbations and lack of anti-inflammatory control. Alternatively, a Leukotriene Receptor Antagonist (LTRA, montelukast 10 mg orally once daily) can be added; montelukast attenuates EIB within 2 hours of administration without tachyphylaxis and offers specific efficacy in cold-weather and aquatic athletes.
• WADA Anti-Doping Regulations: Clinicians and athletes must ensure that all prescribed inhalers fall within the allowable urinary thresholds defined by the World Anti-Doping Agency Prohibited List:
  • Salbutamol: Maximum 1,600 micrograms over 24 hours in divided doses, not to exceed 600 micrograms in any 8-hour period. Urinary threshold: 1,000 ng/mL.
  • Formoterol: Maximum delivered dose of 54 micrograms over 24 hours. Urinary threshold: 40 ng/mL.
  • Salmeterol: Maximum 200 micrograms over 24 hours.
  • Vilanterol: Maximum 25 micrograms over 24 hours.
  • Inhaled corticosteroids are permitted without Therapeutic Use Exemption (TUE) at therapeutic doses. Oral beta-2 agonists and systemic corticosteroids are strictly prohibited in-competition.
• Non-Pharmacologic Strategies & Warm-up Regimens: Structured warm-up protocols induce a “refractory period” of protected airway caliber lasting 1 to 2 hours, mediated by transient depletion of mast cell mediators and compensatory catecholamine and prostaglandin E2 (PGE2) release. The recommended warm-up consists of 15 to 30 minutes of interval exercise: 2 to 3 minutes of high-intensity exertion at 80% to 90% of maximum heart rate followed by 1 to 2 minutes of active recovery, repeated 4 to 6 times. In cold weather (< -10°C), wearing a heat-and-moisture exchanger (HME) face mask effectively humidifies and warms inspired air, blunting bronchoconstrictor responses.
• EILO Respiratory Retraining Therapy: Pharmacotherapy with bronchodilators has zero efficacy in EILO. First-line management is specialized speech-language pathology (SLP) intervention utilizing continuous video feedback:
  • Diaphragmatic Breathing: Re-training from chest and accessory neck breathing to deep diaphragmatic excursion to reduce laryngeal muscle tension.
  • Abduction Release Techniques: Practicing nasal inspiration through a relaxed pharynx paired with pursed-lip or three-phase exhalation (“sniff-hiss” techniques) at the first perception of stridor.
  • Inspiratory Muscle Training (IMT): High-resistance threshold devices (e.g., POWERbreathe) strengthen inspiratory muscles and stabilize the laryngeal airway during maximal hyperpnea.

Operative Interventions

Surgical intervention is indicated for refractory structural abnormalities, vascular compressions, and thoracic wall emergencies:

• Supraglottoplasty for Refractory Supraglottic EILO: In competitive athletes with documented severe supraglottic collapse (CLE grade 3) refractory to intensive speech therapy, surgical supraglottoplasty achieves substantial symptom relief. Under direct suspension microlaryngoscopy with jet ventilation or micro-laryngeal endotracheal intubation, the redundant mucosal folds over the cuneiform cartilages are excised, and tight aryepiglottic folds are divided using a CO2 laser or micro-instruments (cold steel). Postoperative recovery involves 2 weeks of vocal rest, high-dose proton pump inhibitors to prevent laryngeal granuloma formation, and gradual return to training at 4 weeks.
• Tube Thoracostomy & VATS Pleurodesis for Pneumothorax:
  • Emergency Decompression: Tension pneumothorax mandates immediate needle thoracostomy using a 14-gauge catheter placed in the 2nd intercostal space midclavicular line or 4th/5th intercostal space anterior axillary line, immediately followed by tube thoracostomy (16 to 24 Fr chest tube) connected to water seal.
  • VATS Bullectomy & Pleurodesis: For competitive athletes, a conservative “watch-and-wait” approach carries a 30% to 50% recurrence rate. Video-Assisted Thoracoscopic Surgery (VATS) with endoscopic stapler resection of apical subpleural bullae (bullectomy) and mechanical parietal pleural abrasion (or partial pleurectomy) reduces recurrence rates to < 2% to 4%. In high-risk athletes (SCUBA divers, aviators, collision sport competitors), VATS is strongly recommended after the first single episode.
• Multimodal Protocol for Paget-Schroetter Syndrome:
  • Catheter-Directed Thrombolysis (CDT): Initiated within 10 to 14 days of symptom onset. Continuous infusion of tissue plasminogen activator (tPA) restores subclavian vein patency in > 90% of acute presentations.
  • Surgical Thoracic Outlet Decompression: Anticoagulation alone without surgical decompression results in persistent disability, recurrent thrombosis, and secondary venous hypertension in > 60% of athletes. Decompression via transaxillary or paraclavicular resection of the entire first rib, division of the subclavius tendon, and resection of the anterior scalene muscle is performed within 2 to 6 weeks following thrombolysis.
  • Postoperative Balloon Venoplasty: Follow-up venography evaluates persistent intrinsic venous stenosis; residual fibrous strictures are treated with balloon angioplasty. Endovascular stenting across the costoclavicular junction is strictly contraindicated due to inevitable stent fracture from repetitive musculoskeletal crush.

Indications & Contraindications

Decision-making is driven by explicit clinical and diagnostic thresholds:

• Indications for Maintenance Pharmacotherapy in EIB: Post-provocation fall in FEV1 >= 10% on EVH testing with symptoms recurring > 2 times per week despite pre-exercise SABA, or exercise limitation interfering with competitive performance.
• Indications for Supraglottoplasty: Severe supraglottic collapse (CLE grade 3) confirmed on continuous exercise laryngoscopy, failure of a minimum of 8 to 12 weeks of structured SLP respiratory retraining, and severe exercise-limiting stridor with arterial desaturation.
• Indications for Surgical Pleurodesis in Athletes: First episode of primary spontaneous pneumothorax in athletes participating in diving, flying, or collision sports; any second (recurrent) ipsilateral episode; persistent air leak > 4 days; or bilateral spontaneous pneumothorax.
• Absolute Contraindications:
  • LABA monotherapy without concurrent ICS (carries black-box warning for fatal asthma exacerbation).
  • Participation in collision, contact, or high-velocity sports (football, hockey, rugby, martial arts, downhill skiing) while on systemic therapeutic anticoagulation for deep vein thrombosis or pulmonary embolism (severe risk of fatal intracranial or intra-abdominal hemorrhage).
  • Resuming SCUBA diving following pneumothorax without definitive bilateral surgical pleurodesis and formal clearance by a hyperbaric medicine specialist.

9. Outcomes & Return-to-Play Criteria

With precise diagnostic characterization and targeted therapy, athletes across all disciplines can safely regain peak performance while minimizing reinjury or relapse.

• Exercise-Induced Bronchoconstriction (EIB): Stepwise therapy with ICS and pre-exercise SABA achieves complete symptom control and normalizes ventilatory capacity in > 85% to 90% of athletes. Full return-to-play (RTP) is permitted immediately once the athlete is asymptomatic at rest and demonstrates post-exercise FEV1 drops of < 10% under competitive conditions.
• Exercise-Induced Laryngeal Obstruction (EILO): Specialized speech therapy achieves successful symptom management and performance restoration in 60% to 70% of athletes with glottic and mild supraglottic EILO. In severe supraglottic EILO, surgical supraglottoplasty achieves subjective and objective resolution of stridor and dyspnea in > 80% to 90% of patients, with return to full training at 4 to 6 weeks postoperatively.
• Swimming-Induced Pulmonary Edema (SIPE): Acute SIPE typically resolves completely within 24 to 48 hours following supportive management and water extraction. Recurrence rates range from 15% to 30% in subsequent cold-water events. RTP is cleared once resting SpO2 is normal (> 96%), lung auscultation is completely clear, and repeat chest radiography confirms total clearance of alveolar infiltrates. Athletes should return initially to heated pool environments before resuming open-water swimming.
• Primary Spontaneous Pneumothorax: Following successful tube thoracostomy resolution, non-strenuous conditioning can resume at 2 to 3 weeks. Following VATS bullectomy and mechanical pleurodesis, light aerobic training resumes at 3 to 4 weeks, with full contact and collision sport clearance at 8 to 12 weeks once complete radiographic pleural adherence and normal spirometry are documented.
• Effort Thrombosis (Paget-Schroetter): Multimodal protocol consisting of catheter-directed thrombolysis, prompt surgical first rib resection, and post-resection venoplasty yields long-term subclavian vein patency rates of 90% to 95% and allows > 90% of competitive athletes to return to elite overhead performance. Following first rib resection, therapeutic anticoagulation is maintained for 2 to 3 months. Full return to overhead sports (pitching, rowing, swimming) occurs at 3 to 4 months post-resection once anticoagulation has ceased and follow-up duplex ultrasound confirms complete vein patency.
• The IOC “Neck Rule” for Respiratory Infections in Athletes:
  • Symptoms Strictly “Above the Neck”: Rhinorrhea, nasal congestion, sneezing, or mild sore throat without systemic manifestations. Athlete is permitted to perform light, non-strenuous exercise (50% intensity for < 30 minutes). If symptoms do not worsen, intensity can be graduated cautiously over 2 to 3 days.
  • Symptoms “Below the Neck”: Cough, wheezing, dyspnea, substernal tightness, resting tachycardia, generalized myalgias, arthralgias, or systemic fever (>= 38.0°C / 100.4°F). Absolute training cessation is mandatory. Strenuous exercise in the presence of systemic viremia or bacteremia poses severe risks of viral myocarditis, fatal arrhythmias, and rhabdomyolysis. Athletes must remain on complete bed rest until 48 hours completely afebrile without antipyretics, followed by a graduated 5- to 7-day reintroduction protocol.

10. Complications

Complications associated with athletic pulmonary disorders range from subtle chronic training impairments to sudden, life-threatening thoracic and vascular catastrophes.

11. Pearls and Pitfalls

Nuanced clinical insights that distinguish experienced sports medicine and pulmonary specialists include:

• Beware the “Elite Conditioning Paradox”: Highly trained endurance athletes frequently generate resting FEV1 values of 120% to 140% of standard population predicted values. A post-exercise FEV1 drop from 135% down to 105% of predicted represents a profound 22% bronchoconstrictor collapse, yet inexperienced clinicians may erroneously dismiss the post-challenge spirometry as “normal” because the absolute number remains above 100%. Always calculate percentage drop relative to the athlete’s own pre-challenge baseline.
• The Inhaler Technique Void: More than 50% of competitive athletes prescribed metered-dose inhalers (MDIs) perform incorrect administration maneuvers (firing without breath coordination, failing to hold breath for 10 seconds, or inhaling too rapidly). Poor deposition results in drug impaction on the posterior oropharynx rather than lower tracheobronchial delivery. Always mandate the use of a valved holding chamber (spacer) and directly verify inhalation technique at every clinical visit.
• The Audible Phase Test: Listen carefully to where the abnormal sound is generated and in which phase of respiration it occurs. If the athlete makes noise during inspiration and clutches their neck, think EILO; if the noise is quiet, long, and expiratory, think EIB. Never treat inspiratory stridor with escalating doses of inhaled bronchodilators.
• Resist the Temptation to Stent the Subclavian Vein: In Paget-Schroetter syndrome, placing an endovascular stent across the costoclavicular junction without performing surgical first rib resection is a critical error. The immense repetitive scissor forces between the clavicle and first rib inevitably fracture the metal stent struts, inducing catastrophic re-thrombosis, intimal perforation, and near-unsurpassable surgical reconstruction challenges.
• Verify WADA Limits for Every Combination Inhaler: Athletes frequently switch brand formulations while traveling internationally. Inadvertently prescribing a combination inhaler containing an unapproved beta-2 agonist or exceeding daily inhalation limits triggers strict anti-doping liability and potential multi-year athletic suspensions under the World Anti-Doping Code.

12. Current Controversies

Several clinical and regulatory dilemmas remain actively debated in sports pulmonary medicine:

Universal Pre-Participation Screening for Airway Dysfunction

Proponents of mandatory pre-participation pulmonary screening argue that because respiratory symptoms fail to predict objective EIB in more than 40% of elite athletes, universal screening with EVH would identify occult airway disease, prevent sudden exercise-induced respiratory compromise, and optimize athletic performance before major Olympic cycles. Opponents highlight that universal EVH screening is logistically burdensome, cost-prohibitive for large collegiate and club cohorts, and risks medicalizing asymptomatic athletes who demonstrate mild laboratory airway hyperreactivity that has zero clinical impact on competitive performance.

The Ergogenic Debate: Do Inhaled Beta-2 Agonists Enhance Performance?

A contentious debate persists regarding whether inhaled beta-2 agonists offer an unfair physiological advantage to non-asthmatic athletes. Comprehensive systematic reviews and meta-analyses conducted for WADA have consistently shown that therapeutic inhaled doses of salbutamol, formoterol, or salmeterol do not enhance aerobic endurance, VO2 max, or sprint cycling performance in athletes without EIB. However, supratherapeutic doses administered orally or parenterally exert profound anabolic and central stimulatory effects, increasing skeletal muscle mass and lipolysis. Ongoing scrutiny focuses on whether high-dose inhaled administration at the maximum permissible WADA boundary might provide subtle ergogenic bronchodilatory or psychomotor benefits under extreme environmental stress.

Diagnostic Overlap & Co-existence of EIB and EILO

Historically considered mutually exclusive diagnostic entities, modern high-volume exercise laboratory data reveal that between 15% and 25% of elite athletes with refractory exertional dyspnea have concomitant, overlapping EIB and EILO. When an athlete with verified EIB fails to achieve symptomatic control despite escalating ICS/LABA therapy, clinicians frequently escalate pharmacotherapy inappropriately instead of suspecting secondary supraglottic or glottic EILO. Establishing dual-provocation diagnostic protocols that integrate EVH with continuous exercise laryngoscopy represents the emerging standard in specialized sports cardiology and pulmonary centers.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Reier-Nilsen T, Sewry N, Chenuel B et al. Diagnostic approach to lower airway dysfunction in athletes: a systematic review and meta-analysis by a subgroup of the IOC consensus on ‘acute respiratory illness in the athlete’. Br J Sports Med. 2023. doi:10.1136/bjsports-2022-106059 [Level I: Systematic Review / Meta-Analysis]
• Parsons JP, Hallstrand TS, Mastronarde JG et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2013. doi:10.1164/rccm.201303-0437ST [Level IV: Clinical Practice Guideline / Consensus]
• Schwellnus M, Adami PE, Bougault V et al. International Olympic Committee (IOC) consensus statement on acute respiratory illness in athletes part 2: non-infective acute respiratory illness. Br J Sports Med. 2022. doi:10.1136/bjsports-2022-105567 [Level IV: Consensus Statement / Clinical Cohort Synthesis]
• Halvorsen T, Walsted ES, Bucca C et al. Inducible laryngeal obstruction: an official joint European Respiratory Society and European Laryngological Society statement. Eur Respir J. 2017. doi:10.1183/13993003.02221-2016 [Level IV: Consensus Statement / Diagnostic Recommendation]
• Carlsen KH, Anderson SD, Bjermer L et al. Exercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN. Allergy. 2008. doi:10.1111/j.1398-9995.2008.01662.x [Level IV: Task Force Report / Clinical Case Series]

15. Master Class Pro-Tip

“When assessing an elite endurance athlete with unexplained exertional dyspnea, never rely on resting office spirometry or patient questionnaires alone. High-performance athletes possess vast ventilatory reserves and will often blow normal or supranormal resting numbers even in the face of significant pathology. Always subject the athlete to a formal objective challenge: perform Eucapnic Voluntary Hyperpnea (EVH) to uncover lower airway bronchoconstriction, and never hesitate to advance to Continuous Laryngoscopy during Exercise (CLE) if symptoms peak at maximal effort. Remember the golden clinical rule: expiratory noise that peaks after exercise is bronchial (EIB); inspiratory noise that peaks at the height of exercise is laryngeal (EILO). Differentiating the two spares the athlete months of unnecessary steroid inhalers and unlocks targeted, curative respiratory retraining.”

Master Class Clinical Pearl: Athletic Pulmonary Assessment